Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY 4.0Beilstein Journal of Nanotechnology

Curcumin pharmacology and pharmacokinetics: current challenges and future perspectives in nanoemulsion delivery

  • Daniele De Campos1
  • Marciane Zornita Bortolanza2
  • Mohamed Fathi Abdallah3
  • Jean-Marie Colet4
  • Julia de Oliveira Primo1
  • Carla Bittencourt1
  • Najeh Maissar Khalil2
4 affiliations
  1. 1Chimie Interactions Plasma-Surface (ChIPS), Research Institute for Materials Science and Engineering, University of Mons, Av. Nicolas Copernic 3, 7000 Mons, Belgium
  2. 2Applied Nanostructured Systems Laboratory, Universidade Estadual do Centro-Oeste, UNICENTRO, Alameda Elio Antonio Dalla Vecchia, 838, 85040-167, Guarapuava, PR, Brazil
  3. 3Department of Food Science, Aarhus University, Agro Food Park 48, 8200 Aarhus, Denmark
  4. 4School of Medicine and Pharmacy, Biologie humaine et Toxicologie, University of Mons, Avenue du Champ de Mars, 7000 Mons, Belgium
Read full textPDFDOICite

Abstract

Derived from the rhizome of Curcuma longa L., curcumin has evolved from a traditional component of South Asian medicine into a prominent topic in modern pharmacology. Curcumin has a pleiotropic pharmacological profile with biological properties including antioxidant, anti-inflammatory, and anticancer effects. However, its clinical translation faces physiological and chemical challenges, characterized by low systemic bioavailability, instability at neutral to alkaline pH, and rapid metabolic clearance. This review examines the molecular mechanisms and biological barriers that limit its efficiency and explores nanotechnology as a strategy to optimize its pharmacokinetic profile. It focuses on nanostructured systems, emphasizing nanoemulsions, to improve stability and prolong systemic circulation. Finally, the current landscape of clinical studies and the prospects for using these nanosystems to manage inflammatory and oncological diseases are discussed to establish curcumin as a therapeutic alternative.

Related

  1. Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery
    Alanzi Abdullah R., Fatima Iman, Ashraf Muhammad Umer +6
    Open Life SciencesPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaDOAJ
  2. Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives
    Emma Safran, Howard Safran, Stanley Kim
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  3. Curcumin in solid organ transplantation: current evidence, mechanisms, and translational challenges
    Lubiao Liang, Wei Xiong, Chunyang Guo +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  4. Phytochemical basis, multitarget pharmacology, and translational perspectives of silymarin: emphasis on its antifibrotic effects
    Zhe Jin, Jing Zhu, Binghong Lu +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyDOAJCrossref
  5. Intracranial Hemorrhage in Patients Receiving Factor Xa Inhibitors: Challenges and Perspectives
    Ryuki Chatani
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{campos2026curcumin,
  title = {{Curcumin pharmacology and pharmacokinetics: current challenges and future perspectives in nanoemulsion delivery}},
  author = {Daniele De Campos and Marciane Zornita Bortolanza and Mohamed Fathi Abdallah and Jean-Marie Colet and Julia de Oliveira Primo and Carla Bittencourt and Najeh Maissar Khalil},
  journal = {Beilstein Journal of Nanotechnology},
  year = {2026},
  month = oct,
  doi = {10.3762/bjnano.17.102},
  url = {https://doi.org/10.3762/bjnano.17.102},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Curcumin pharmacology and pharmacokinetics: current challenges and future perspectives in nanoemulsion delivery
AU  - Daniele De Campos
AU  - Marciane Zornita Bortolanza
AU  - Mohamed Fathi Abdallah
AU  - Jean-Marie Colet
AU  - Julia de Oliveira Primo
AU  - Carla Bittencourt
AU  - Najeh Maissar Khalil
PY  - 2026
DA  - 2026/10/29
JO  - Beilstein Journal of Nanotechnology
DO  - 10.3762/bjnano.17.102
UR  - https://doi.org/10.3762/bjnano.17.102
AB  - Derived from the rhizome of Curcuma longa L., curcumin has evolved from a traditional component of South Asian medicine into a prominent topic in modern pharmacology. Curcumin has a pleiotropic pharmacological profile with biological properties including antioxidant, anti-inflammatory, and anticancer effects. However, its clinical translation faces physiological and chemical challenges, characterized by low systemic bioavailability, instability at neutral to alkaline pH, and rapid metabolic clearance. This review examines the molecular mechanisms and biological barriers that limit its efficiency and explores nanotechnology as a strategy to optimize its pharmacokinetic profile. It focuses on nanostructured systems, emphasizing nanoemulsions, to improve stability and prolong systemic circulation. Finally, the current landscape of clinical studies and the prospects for using these nanosystems to manage inflammatory and oncological diseases are discussed to establish curcumin as a therapeutic alternative.
SN  - 2190-4286
ER  -